Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 6:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Jacksonville, Florida Clear all
Completed Phase 2 Interventional Results available

Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

NCT03554083
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Interventions
Atezolizumab, Cobimetinib, Tiragolumab, Vemurafenib
Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Jacksonville, Florida • Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 7, 2026, 6:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mechanisms of Cell Death in Spinal Muscular Atrophy

NCT01754441
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
Up to 21 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2020
U.S. locations
2
States / cities
Wilmington, Delaware • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Jun 7, 2026, 6:20 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant

NCT03057054
View directory record Official record
Conditions
Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, Leukemia, Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Lactobacillus plantarum strain 299, Lactobacillus plantarum strain 299v, Placebo Administration
Procedure · Biological · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 25 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
40
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Jun 7, 2026, 6:20 AM EDT
Recruiting Phase 3 Interventional

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

NCT05624996
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Computed Tomography, Durvalumab, Etoposide, Image Guided Radiation Therapy, Nab-paclitaxel, Osimertinib, Paclitaxel, Pemetrexed, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Procedure · Biological + 2 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
470
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 352 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 7, 2026, 6:20 AM EDT
Enrolling by invitation Phase 4 Interventional

Longitudinal Imaging Biomarkers of Disease Progression in DLB

NCT03582488
View directory record Official record
Conditions
Lewy Body Disease
Interventions
18F-Flortaucipir
Drug
Lead sponsor
Kejal Kantarci
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jun 7, 2026, 6:20 AM EDT
Active, not recruiting No phase listed Observational

The REPLACE Registry for Cholbam® (Cholic Acid)

NCT03115086
View directory record Official record
Conditions
Bile Acid Synthesis Disorders
Interventions
Cholbam
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2039
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients

NCT02290873
View directory record Official record
Conditions
Colonoscopy
Interventions
Remimazolam, Midazolam, Placebo
Drug
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Mobile, Alabama • Anaheim, California • Chula Vista, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 3 Interventional

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00333151
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, rosiglitazone, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
71
States / cities
Goodyear, Arizona • Colton, California • Concord, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Results available

Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors

NCT01508702
View directory record Official record
Conditions
Gout
Interventions
lesinurad, Placebo
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
79
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 3 Interventional

A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression

NCT00128479
View directory record Official record
Conditions
Major Depressive Disorder, Psychotic Disorders
Interventions
mifepristone, mifepristone matched placebo, mifepristone 600 mg, mifepristone 1200 mg
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
44
States / cities
Little Rock, Arkansas • Cerritos, California • Fountain Valley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Results available

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

NCT01450761
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Ipilimumab, Placebo matching Ipilimumab, Etoposide, Cisplatin, Carboplatin
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
42
States / cities
Hot Springs, Arkansas • Auburn, California • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Jun 7, 2026, 6:20 AM EDT
Active, not recruiting Phase 3 Interventional

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

NCT05678673
View directory record Official record
Conditions
Non-Clear Cell Renal Cell Carcinoma
Interventions
XL092, Nivolumab, Sunitinib Malate
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Duarte, California • Newport Beach, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

IV SafeLock Device Functionality in Emergency Department

NCT05695183
View directory record Official record
Conditions
Intravenous Access
Interventions
IV SafeLock
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jun 7, 2026, 6:20 AM EDT
Terminated Phase 1 Interventional

Topical Rapamycin/Sirolimus for Complicated Vascular Anomalies and Other Susceptible Lesions

NCT04172922
View directory record Official record
Conditions
Vascular Anomaly
Interventions
Topical Sirolimus
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
36 Months to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Jacksonville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 2 Interventional

Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors

NCT00039494
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
erlotinib hydrochloride, 3-dimensional conformal radiation therapy, temozolomide
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
139
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 82 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Jun 7, 2026, 6:20 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

NCT03930953
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
CC-99282, Rituximab, Obinutuzumab, Tafasitamab, Valemetostat
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jun 7, 2026, 6:20 AM EDT
Recruiting Phase 3 Interventional

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT05712200
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
Abelacimab, Placebo
Biological · Drug
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
1,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
150
States / cities
Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jun 7, 2026, 6:20 AM EDT
Recruiting Phase 3 Interventional

E-Mindfulness Approaches for Living After Breast Cancer

NCT06748222
View directory record Official record
Conditions
Breast Cancer, Depression
Interventions
Mindfulness (MAPs) Live Online, Mindfulness (MAPs) Digital App, Meditation Only Control Group
Behavioral
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 50 Years
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
332
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 280 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 7, 2026, 6:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C"

NCT04144751
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Blood Sample Collection
Other
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
40 Years and older
Enrollment
23,494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
194
States / cities
Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 160 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine

NCT02974153
View directory record Official record
Conditions
Migraine Disorders
Interventions
ALD403 (Eptinezumab), Placebo
Biological
Lead sponsor
Alder Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Results available

Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

NCT00068445
View directory record Official record
Conditions
Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
lamotrigine, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
23
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Atlanta, Georgia + 20 more
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Jun 7, 2026, 6:20 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Personalized Education and Genetic Counseling to Increase Genetic Testing in Patients With a Known Family History of Pancreatic Cancer

NCT06744595
View directory record Official record
Conditions
Pancreatic Carcinoma
Interventions
Biospecimen Collection, Educational Intervention, Electronic Health Record Review, Genetic Counseling, Genetic Testing for Cancer Risk, Survey Administration
Procedure · Other · Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients

NCT00064701
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Tacrolimus Modified Release (MR), Tacrolimus, cyclosporine microemulsion, mycophenolate mofetil
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
12 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
48
States / cities
Birmingham, Alabama • Mobile, Alabama • Loma Linda, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Jun 7, 2026, 6:20 AM EDT
Terminated Phase 3 Interventional Results available

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

NCT02312206
View directory record Official record
Conditions
Primary Systemic (AL) Amyloidosis
Interventions
NEOD001, Placebo
Drug · Other
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
32
States / cities
Scottsdale, Arizona • Duarte, California • Stanford, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Jun 7, 2026, 6:20 AM EDT